Previous 10 | Next 10 |
home / stock / huma / huma articles
The trading activity of members of Congress continues to draw increased attention from investors with the potential that conflicts of interest, inc...
U.S. stock futures were mixed this morning, with the Dow futures falling around 50 points on Monday. Shares of AMC Networks Inc. (NASDAQ:AMCX) fell...
Shares of Core & Main Inc (NYSE:CNM) fell sharply during Tuesday's session after the company reported mixed first-quarter financial result...
Shares of Super Micro Computer, Inc. (NASDAQ:SMCI) fell sharply during Friday's session. The company announced its third-quarter earnings date...
U.S. stocks were mixed, with the Nasdaq Composite falling over 100 points on Friday. Shares of Fifth Third Bancorp (NASDAQ:FITB) rose during Friday...
U.S. stocks were lower, with the Nasdaq Composite falling over 50 points on Thursday. Shares of Ally Financial Inc. (NYSE:ALLY) rose sharply during...
DURHAM, N.C., March 26, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing univer...
-Biologics License Application (BLA) for HAV™ Accepted by FDA on February 8, 2024- -BLA Granted Priority Review for Vascular Trauma Indicat...
The CNN Money Fear and Greed index showed a slight increase in the overall market sentiment on Thursday. U.S. stocks closed higher on Thursday...
News, Short Squeeze, Breakout and More Instantly...
DURHAM, N.C., July 16, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, announced the addition of pharmaceutical industry veteran Dr. John P. Bamforth and di...
Pluristyx, a leading provider of tools, technologies, and services for the development of cellular therapies, is pleased to announce a license agreement with Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercia...
2024-07-01 10:28:20 ET Humacyte Inc (NASDAQ: HUMA) opened close to 25% up on Monday after the Food & Drug Administration granted its ATEV a special advanced-therapy designation. Shares of the biotech firm are still down some 30% versus their year-to-date high. Why does it ma...